Sign up USA
Proactive Investors - Run By Investors For Investors

Mylan heads lower as it receives “tentative approval” for HIV/AIDS drug

The treatment combines three first-line therapies – Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate – into one smaller tablet that patients take three times a day
african man having blood sample taken at doctor's
There are currently around 37mln people living with HIV/AIDS around the world

Shares in Mylan Inc. (NASDAQ:MYL) dropped in pre-market trade on Monday after the pharma giant confirmed it has received “tentative approval” for its TLD HIV/AIDS antiretroviral (ARV) drug.

The treatment combines three first-line therapies – Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate – into one smaller tablet that patients take three times a day.

It’s the first fixed-dose combination of its kind to be offered to patients being treated for HIV/AIDS, Mylan said.

The US Food and Drug Administration gave its ‘tentative approval’ under the US President’s Emergency Plan for AIDS Relief – a governmental initiative designed to address the global HIV/AIDS epidemic, but with a particular focus on Africa.

“Our innovative TLD is a new medicine that will be available specifically to patients in the developing world being treated for HIV/AIDS,” said chairman Rajiv Malik.

“We know the challenges they face accessing high quality, affordable ARVs. That's why our scientists worked diligently to develop a medicine that combines three of the leading first-line regimens into a new, smaller tablet that patients have to take only once each day.”

Shares were down 4.5% in pre-market to US$31.35.

View full MYL profile View Profile

Mylan Inc. Timeline

Related Articles

Cholesterol gauge
July 25 2017
The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use